Amphetamine induces accumulation of the norepinephrine transporter into Rab4- and Rab11-positive compartments by Moore, Jessica Lauren
   
AMPHETAMINE INDUCES ACCUMULATION OF THE NOREPINEPHRINE 
TRANSPORTER INTO RAB4- AND RAB11-POSITIVE COMPARTMENTS 
By 
Jessica Moore 
 
Thesis 
Submitted to the Faculty of the  
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements  
for the degree of  
 
MASTER OF SCIENCE 
in 
 
Interdisciplinary Studies: Membrane Transporter Biology 
 
May, 2009 
 
Nashville, Tennessee 
 
 
Approved: 
Aurelio Galli 
Roger Colbran
  ii 
ACKNOWLEDGMENTS 
 
This work would not have been possible without research and training funding 
from the National Institute of Mental Health. 
For help in completion of this work, I especially thank Heiner Matthies and 
Christine Saunders.  I also thank the rest of the Galli lab, Erica Bowton, Concetta 
Dipace, Sabrina Doughty, Kevin Erreger, Brandon Lute, and Nicole Speed for 
their advice and assistance.  I thank my advisor, Aurelio Galli, for his help 
directing the project, providing funding, and for his support throughout my time in 
his lab.  
For their understanding, willingness to listen, faith in me, and encouragement to 
pursue alternatives and to follow my instincts, I thank my friends Elisabeth 
Loecken, Bethany Packard, Laura Johns Fowler, Christal Sohl, Nicole Speed, 
Suzanne Blank, Tyler Bond, Erin Cosyn, Holly Hosman, and Sarah Kurley.  Most 
importantly, I thank my mom, dad, and brothers for their love and support 
throughout my life. 
  iii 
TABLE OF CONTENTS 
 
Page 
ACKNOWLEDGMENTS ....................................................................................... ii 
LIST OF FIGURES .............................................................................................. iv 
LIST OF ABBREVIATIONS .................................................................................. v 
Chapter 
I. INTRODUCTION………………………………………………………………..1 
 Norepinephrine transporter structure and function…………………………………..1  
 Sites of NET expression………………………………………………………………..4 
 Genetic manipulation of NET…………………………………………………………..4 
 Human disorders related to NET and amphetamine…………………………….….5 
 AMPH as therapy and abused drug…………………………………………………..7 
 AMPH’s actions on NET………………………………………………………………..8 
 NET’s residence in endosomes………………………………………………………11 
   
 
II. MATERIALS AND METHODS…….…………………………………………14  
III. RESULTS………………………………………………………………………18 
  
AMPH leads to a decrease in NET surface expression…………………………..18 
 AMPH increases colocalization of NET with Rab4 and Rab11…………………..22 
 NET trafficking involves Rab4 and Rab11 function………………………………..24 
 
IV. DISCUSSION...…………………………………………………………………29 
  
 AMPH-induced NET internalization in terminal boutons…………………………..29 
 Basal NET distribution in neurons……………………………………………………29 
Similarity to other SLC5 transporters................................................................. 30 
Possible relation to AMPH-induced signaling .................................................... 31 
 NET reserve pool hypothesis………………………………………………………...32 
 Effect of blocking Rab function on AMPH-induced NET internalization...……….33 
 Conclusions…………………………………………………………………………….34 
 Significance……….……………...…………………………………………………….34 
 
REFERENCES………………………………………….………………………………35
  iv 
 
FIGURES 
 
Figure              Page 
1:  NET topology and LeuT structure .............................................................................. 2 
2:  Mechanism of NE transport by NET........................................................................... 3 
3:  Model for AMPH regulation of NET trafficking .......................................................... 12 
4:  AMPH decreases NET surface expression .............................................................. 19 
5:  AMPH increases intracellular NET in terminal boutons ............................................ 19 
6:  AMPH decreases proportion of NET co-fractionating with Na+/K+ ATPase ............. 21 
7:  NET co-fractionates with Rab4 and Rab11 following AMPH treatment..................... 23 
8:  AMPH increases colocalization of NET with Rab4 and Rab11 ................................. 25 
9:  Disrupting Rab4 or Rab11 function blocks AMPH-induced NET internalization........ 27 
  v 
 
ABBREVIATIONS 
 
ADHD: attention deficit hyperactivity disorder 
Akt: protein kinase B 
AMPH: amphetamine 
CNS: central nervous system 
DA: dopamine 
DAT: dopamine transporter 
DN: dominant negative 
ERC: endocytic recycling compartment 
FIP2: Rab11 family interacting protein 2 
ICQ: intensity correlation quotient 
KO: knockout 
LC: locus ceruleus 
NE: norepinephrine 
NET: norepinephrine transporter 
PBS: phosphate buffered solution 
PKC: protein kinase C 
PNS: peripheral nervous system 
SCG: superior cervical ganglion 
SE: sorting endosome 
SERT: serotonin transporter 
SLC6: sodium- and chloride-dependent neurotransmitter transporter 
TfR: transferring receptor 
TM: transmembrane
  1 
CHAPTER I 
 
INTRODUCTION 
 
I-1 Neurotransmitter transporters 
Precise neurotransmitter signaling requires a means of transmitter removal from the 
synapse, controlling the intensity and duration of the signal.  Either enzymatic 
degradation or cellular uptake, or a combination of these, may remove transmitter from 
the extracellular space.  As early neurotransmitter studies focused on acetylcholine, 
biologists first assumed that removal of all transmitters occurred similarly, via 
degradation by specific enzymes.  However, Axelrod’s experiments using radioactively 
labeled norepinephrine (NE) showed that tissues take up NE, leading to the hypothesis 
that reuptake by the releasing neuron contributes significantly to inactivation of 
transmitters other than acetylcholine (Hertting and Axelrod 1961).  Additional 
experiments with other labeled transmitters indicated that inactivation of gamma-
aminobutyric acid (GABA) and glutamate occurs through the same mechanism, further 
supporting this idea (Iversen LL 1971).   
Molecular identification of the proteins responsible for uptake of each transmitter led to 
further evidence of the importance of their function, through the association of mutations 
in transporter genes with disease and the effects of engineered disruption of those 
genes.  For example, a missense mutation in the gene for a glutamate transporter, 
excitatory amino acid transporter 2, identified in an amyotrophic lateral sclerosis patient, 
reduces its function by half, causing increased extracellular glutamate which likely 
contributes to the excitotoxic motor neuron degeneration of that disorder (Aoki M 1998, 
Trotti D 2001).  Similarly, a coding polymorphism in the serotonin transporter (SERT), 
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identified in patients displaying symptoms of obsessive compulsive disorder plus 
Asperger’s syndrome or anorexia nervosa, doubles its uptake function, which likely 
causes altered behavior by reducing serotonergic signaling (Ozaki N 2003, Kilic F 2003).   
The mutation in the norepinephrine transporter (NET, see section I-5) identified in  
patients with orthostatic intolerance provides yet another example, showing the 
necessity of proper transmitter signal termination (Shannon JR 2000).   
The effects of inactivation of one of the transporter genes, as they occur in a controlled 
background, support a causative role of spontaneous mutations in transporter genes in 
human disease and allow direct examination of transporters’ role in controlling 
transmitter concentrations.  Knockout of any one of these transporters prolongs the 
extracellular lifetime of neurotransmitter; for example, mice lacking the DA transporter 
(DAT) clear DA 300 times slower than wildtype mice (Jones SR 1998).  Altered 
transmitter dynamics affect behavior as well as vital functions.  For example, mice 
lacking functional GABA transporter subtype 1 (GAT1) have disordered movement as 
well as activity patterns indicating increased anxiety (Chiu CS 2005).  Mice lacking 
SERT display irregular colon motility, while disrupting the NET gene affects 
cardiovascular function (Chen JJ 2001, Keller NR 2004, also see section I-4).   
The work described in this thesis investigates the effects of amphetamine (AMPH) on 
NET’s subcellular distribution, particularly the specific compartment in which NET 
accumulates following AMPH exposure.  The remainder of this introduction therefore 
describes NET in more detail, as well as AMPH’s effects on NET function and 
localization and on physiological functions that result from effects on NET. 
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I-2 Norepinephrine transporter function and structure 
Expression cloning identified the norepinephrine transporter (NET) as the protein 
responsible for reuptake of norepinephrine (NE) (Pacholczyk T 1991), already 
determined to be the major means of NE clearance (Iversen 1967; lversen 1975).  
Cloning also revealed NET’s amino acid sequence, allowing prediction of its topology 
(Pacholczyk T 1991).  NET contains 12 transmembrane (TM) spanning helices, 
intracellular amino and carboxy termini, and a large glycosylated extracellular loop 
between the third and fourth TM domains, as do all members of the sodium and 
chloride-dependent cotransporter family SLC6, which includes the DAT, SERT, and 
GAT1 (Fig. 1A) (Torres GE 2003; Chen NH 2004).  Finally, NET likely functions as a 
dimer, as monomers of hNET with distinct antigenicity can be co-immunoprecipitated 
(Kocabas AM 2003).  Further, a NET mutant that fails to traffic to the cell surface 
prevents wildtype transporter from reaching the surface, indicating that NET forms imers 
prior to cell-surface delivery (Hahn MK 2003). 
These transporters move substrate intracellularly by coupling transport to the diffusion of 
Na+ ions down their concentration gradients.  Radioactive uptake studies led to the 
proposal of the alternating access model, in which binding of one Na+ ion to a NET 
facing the  extracellular space (with its internal gate closed) facilitates binding of one 
molecule of NE, which induces a change to an inward-facing conformation of NET (with 
its outer gate closed) (Fig. 2A-B) (Jardetzky O 1966).  NET then releases the ions and 
NE, which allows NET to return to its outward-facing conformation.    Current recordings 
from cells heterologously expressing NET, however, demonstrated far greater currents 
than predicted by the stoichiometry of the alternating access model, suggesting that NET 
also functions as an NE-gated channel (Fig. 2C) (Galli A 1996).  Further description of 
NET structure followed the determination of the crystal structure of a homologous  
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Figure 1.  Norepinephrine transporter structure.  A, NET topology.  
Each circle represents an amino acid.  Letters indicate N and C termini.  
Pitchfork shapes indicate sites of glycosylation.  From Pacholczyk et. al. 
1991.  B, Crystal structure of the Aquifex aeolicus leucine transporter, a 
NET homolog.  Red and green indicate distinct monomers.  Numbers 
indicate the position of transmembrane domains within the protein 
sequence.  Yellow and blue space-filling structures represent bound 
substrate and ions, respectively.  From Yamashita et. al. 2005. 
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Figure 2.  Mechanism of NE transport by NET.  A-B.  Alternating access 
model.  A indicates the outward-facing conformation, which allows ion and 
substrate from the extracellular space to bind, causing a change in conformation 
to inward-facing (B), where ions and substrates are released into the cytoplasm.  
C indicates the channel mode of the transporter, which allows ions and substrate 
to diffuse through the channel.  The length of the arrows signifies the probability of 
changing between modes.  Courtesy of Kris Kahlig, Vanderbilt University. 
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bacterial leucine transporter, which identified the binding sites for substrate and Na+, as 
well as the internal and external gates (Fig. 1B) (Yamashita A 2005).  
 
I-3 Sites of NET expression 
Comprehensive understanding of AMPH’s effects via NET necessitates description of 
NET’s expression pattern throughout the body, as systemically administered AMPH 
would reach all of these. Noradrenergic neurons in both the central nervous system 
(CNS) and the periphery, as well as the adrenal medulla, express NET protein, and 
functional and pharmacological evidence point toward expression in the lung and 
placenta as well (Schroeter S 2000; Eisenhofer G 2001). The CNS NE system includes 
two major noradrenergic cell groups, the locus ceruleus (LC) of the dorsorostral pons 
and lateral tegmental nuclei (LTN) of the medulla.  The LC projects via the dorsal 
noradrenergic bundle throughout the cortex, as well as to the hippocampus and ventral 
tegmental area (VTA) of the midbrain, and the LTN project via the ventral noradrenergic 
bundle to the hypothalamus and thalamus.  Both nuclei innervate the thalamus, 
amygdala, cerebellum, and spinal cord.  Peripheral noradrenergic nuclei originate in the 
sympathetic ganglia, located paravertebrally, prevertebrally, or previscerally (adjacent to 
target organs), and project to nearly every organ of the body, including the heart, blood 
vessels, trachea and bronchi, liver, smooth muscle of the gastrointestinal tract, and 
urinary and reproductive organs.    
 
I-4 Genetic manipulation of NET 
NET knockout (NET KO) mice have increased basal extracellular NE levels due to 
slowed NE clearance ((Xu F 2000)).  This genetic manipulation also alters DA 
homeostasis; extracellular DA levels in the striatum decrease, leading to supersensitivity 
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of the D2 and D3 types of DA receptors (Xu F 2000).  Lack of uptake of DA by NET may 
contribute to these effects on the DA system; NET’s affinity for DA is greater than that for  
NE, and a NET-selective inhibitor increases extracellular DA in the prefrontal cortex 
(PFC) (Carboni E 1990; Di Chiara G 1992; Giros B 1994; Gu H 1994).  Uptake studies in 
NET KO mice provide more direct evidence for this explanation: cortical and striatal 
synaptosomes from NET KO mice show reduced uptake of [3H] DA, and a DAT-selective 
blocker does not further reduce uptake in the PFC (Morón JA 2002).  These alterations 
have diverse behavioral effects related to many psychiatric and neurological conditions.  
NET knockout (NET KO) mice respond in the forced-swim and tail suspension tests 
similarly to wildtype (WT) mice treated with antidepressants (Xu F 2000).  These mice 
also have reduced locomotor activity in novel environments, lowered seizure threshold 
and seizure severity, and increased pain threshold and opioid analgesia in the warm-
water tail flick test (Bohn LM 2000; Ahern TH 2006; Mitchell HA 2006).  Such behavioral 
results support NET’s involvement in regulation of mood and motivation, attention, 
overall brain excitability, and pain sensation.  Disruption of NET also alters 
cardiovascular function and regulation of energy homeostasis.  NET KO mice display 
tachycardia and hypertension during activity and weigh less than WT mice (Xu F 2000; 
Keller NR 2004). 
 
I-5 Human disorders related to NET and AMPH 
AMPH use causes improved mood or euphoria, suppression of appetite, accelerated 
heart rate, increased blood pressure, and improved concentration.  Though AMPH 
targets DAT and SERT as well as NET, these effects likely at least partially result from 
AMPH’s actions on NET, as related symptoms characterize several human disorders 
associated with variation in the NET gene or treated by NET-specific drugs.  For 
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example, the persistent low mood and negative emotions of depression improve with 
NET inhibitors, such as desipramine, reboxetine, and venlafaxine.   
Polymorphisms in the NET gene may cause some cases of depression; the T182C 
variant in the NET promoter associates with depression in a Japanese as well as a 
Korean population (Inoue K 2004; Ryu SH 2004), and a study including the effects of 
negative life events showed an increased effect of this polymorphism and demonstrated 
an effect of another 5’ upstream variant, G1287C, on risk for depression for which other 
groups had failed to show association (Owen D 1999; Sun N 2008).  A refined approach, 
subdividing the population according to specific symptoms, found association of T182C 
with recurrent depression and of A3081T with increased appetite (Hahn MK 2008).  
Genetic variation in NET may also affect appetite and eating behavior when altered in 
the absence of depression; another variant upstream of the NET gene associates with 
anorexia nervosa (Urwin RE 2002), and variation in this region contributes to differences 
in response to a DAT/ NET blocker for obesity (Spraggs CF 2005).   
Though these and other examples of association evidence suggest NET’s involvement 
in a variety of disorders, only one coding variant yet exists that demonstrates a direct, 
simple relationship between NET and a specific disorder.  The variant of NET in which a 
proline replaces the more common alanine at position 457 causes orthostatic 
intolerance, a type of dysautonomia characterized by lightheadedness, syncope, and 
postural tachycardia (Shannon JR 2000).  This variant functions as a dominant-negative, 
preventing cell-surface delivery of wildtype transporter (Hahn MK 2003).   Altered NET 
function in the periphery also likely contributes to misregulation of blood pressure; 
patients with essential hypertension show increased NE spillover from the heart and 
kidney (Esler M 1988).  Further, several separate coding variants identified in patients 
with either hypertension or hypotension show altered uptake function (Halushka MK 
1999 ; Hahn MK 2005).  The specific norepinephrine reuptake inhibitors atomoxetine 
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and venlafaxine cause slight increases in blood pressure (Mayer AF 2006; Rynn MA 
2007).   
These drugs, especially atomoxetine, treat symptoms of attention deficit hyperactivity 
disorder (ADHD).  Eight to nine percent of US children 8-15 years old meet the DSM-IV 
criteria for ADHD: six or more symptoms of inattention (e.g., does not appear to listen 
when spoken to directly, often loses things needed for important tasks, etc.) or six or 
more symptoms of hyperactivity/impulsivity (e.g., fidgeting or squirming, difficulty being 
quiet, interrupting others often, etc.) to a disruptive and inappropriate degree (Froehlich 
TE 2007, CDC website).  Atomoxetine’s therapeutic value may  lie in its effects on DA 
signaling; it increases extracellular DA as well as NE in the PFC, indicating that 
excessive DA reuptake by NET may underlie ADHD symptoms (Bymaster FP 2002).  
Variation in the NET gene may also contribute directly to the disorder itself; several 
studies have shown association between NET polymorphisms and ADHD (Bobb AJ 
2005; Kim CH 2008; Kim JW 2008), though many others have failed to show association 
(Xu X 2005; Cho SC 2008). 
 
I-6 AMPH as therapy and abused drug 
Treatment of ADHD, narcolepsy, and, historically, obesity includes AMPH, which targets 
NET, as well as DAT and SERT.  Common medical opinion holds that its action, as well 
as that of another psychostimulant, methylphenidate (MPH), on DAT contributes most to 
their efficacy for ADHD; nonetheless, atomoxetine’s effectiveness strongly suggests that 
NET plays a significant role.  Additionally, genetic evidence supports NET’s involvement 
in the mechanism of psychostimulant ADHD treatment, as a variant in the NET gene 
associates with response to MPH (Yang L 2004).  AMPH treats the excessive daytime 
sleepiness (EDS) of narcolepsy, but does not alleviate its other symptoms, cataplexy 
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(temporary muscle weakness) and rapid eye movement sleep disturbances.  AMPH 
promotes wakefulness in all individuals, but narcoleptics require very high doses to 
prevent EDS (Mitler MM 1994).  Its efficacy in alleviating this symptom likely requires 
action on DAT in addition to NET; the very similar stimulant methamphetamine does not 
increase wakefulness in DAT KO mice (Wisor JP 2001).  AMPH’s appetite reduction 
effect led to its use to induce weight loss in obese patients, but its hypertensive side 
effects and propensity for abuse put it out of favor.  
Use of the psychostimulants AMPH and cocaine often leads to abuse and addiction, as 
they act on DAT to increase extracellular DA in the nucleus accumbens (NAcc), which 
current addiction theory holds as the basis of reward.  However, NET may also play an 
important role in the abuse potential of psychostimulants.  The NAcc, as well as other 
dopaminergic areas in the reward circuit, receives considerable noradrenergic input.  
Further, specific NET blockers have reduced cocaine consumption by addicts and 
reduced the subjective intense positive effects (‘high’) of AMPH in recent studies, and 
specific NET gene variants associate with these AMPH effects  (Szerman N 2005; 
Dlugos A 2007; Sofuoglu M 2008).   
 
I-7 AMPH’s actions on NET 
I-7.1 AMPH-induced efflux 
AMPH modulates both NET’s transport function and its subcellular localization, and each 
effect increases extracellular concentrations of substrate.  Early pharmacological 
investigations on the effects of AMPH showed that it inhibits [3H]-NE uptake into and 
induces release of previously accumulated [3H]-NE from the brain in vivo and into brain 
tissue in vitro (Glowinski J 1965; Häggendal J 1967; Stein L 1969; Ziance RJ 1972). 
Sequencing of the NET gene allowed later investigations to show, by heterologous 
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expression, that these effects occur due to direct actions of AMPH on NET (Wall SC 
1995; Burnette WB 1996).  The facilitated exchange diffusion model proposed that 
AMPH, by acting as a substrate, increased the number of inward-facing transporters, 
which allowed binding of internal substrate and subsequent reverse transport (Fischer 
JF 1979).   
Recent evidence, such as the differing ion dependence of uptake and efflux of AMPH, 
questions this model (Pifl C 1999).  Electrophysiological studies of DAT, which likely 
responds to AMPH in a very similar fashion to NET, also support a different mechanism 
for AMPH-induced efflux.  As this effect depends on intracellular Na+, AMPH-induced 
inward Na+ current may cause increased outward transport of substrate (Khoshbouei H 
2003).  Further, AMPH-induced efflux seems to involve Ca2+/calmodulin-dependent 
protein kinase II (CaMKII), as AMPH increases intracellular Ca2+ and inhibiting this 
kinase or mutating DAT to prevent its interaction with CaMKII reduces efflux (Gnegy ME 
2004; Fog JU 2006).  This effect of AMPH may involve yet another component, as 
single-transporter recordings show AMPH-induced bursts of DA efflux, suggesting that 
AMPH may induce channel-like activity of DAT (Kahlig KM 2005).   
I-7.2 AMPH-induced transporter internalization 
The work described in this thesis focuses on AMPH-induced NET trafficking, or net 
movement of NET within the cell to a distribution distinct from that observed in basal 
conditions.  AMPH causes a decrease in the proportion of NET molecules on the plasma 
membrane within one hour of application, as shown by cell surface biotinylation (Dipace 
C 2007).  Active transporters likely constitute the population removed from the surface, 
as the magnitude of single-transporter DAT currents does not change upon AMPH 
exposure (Kahlig KM 2004).  This may result from their proximity to AMPH molecules 
transported into the cell; the failure of uptake-impaired DAT to traffic in response to 
AMPH, combined with the ability of intracellular AMPH to cause DAT internalization, 
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suggests that transport of AMPH must precede trafficking (Kahlig KM 2006).  AMPH may 
reduce numbers of NET on the cell surface by decreasing rates of return of recycling 
NET to the plasma membrane, by increasing rates of endocytosis, or both.  AMPH 
effects on NET trafficking may mimic those on DAT, which probably involve faster 
internalization, as dominant negative (DN) dynamin I reduces AMPH-induced reduction 
of uptake and cell surface expression (Saunders C 2000).   
AMPH might accelerate NET internalization by inducing its ubiquitination, as a recent 
review suggests may occur for DAT (Miranda and Sorkin 2007).  These authors 
hypothesize that amphetamine’s activation of protein kinase C (PKC) would cause 
ubiqitination of the transporter.  PKC induces DAT ubiquitination, as demonstrated by 
mass spectrometry, immunoblotting, and fluorescence resonance energy transfer 
(Miranda M 2005).  Reducing protein levels of a specific E3 ligase, Nedd4-2, by RNA 
interference or mutation of specific lysine residues in DAT’s N terminus decreases the 
ubiquitination of DAT caused by PKC activation, further strengthening this conclusion 
(Sorkina T 2006, Miranda M 2007).  However, whether AMPH-induced DAT 
internalization requires PKC remains unclear.  Neither mutation of DAT C-terminal 
residues required for PKC-induced trafficking nor inhibition of PKC activity affects 
AMPH-regulated DAT trafficking (Boudanova E 2008).  Knockdown of PKC or use of a 
variety of PKC inhibitors rather than a single pharmacological agent would provide more 
conclusive results.  AMPH might also cause ubiquitination of DAT and/or NET 
independently of PKC. 
As inward transport of AMPH by NET likely precedes internalization of NET, it logically 
follows that AMPH would activate intracellular signaling pathways.  Indeed, AMPH-
induced NET internalization involves multiple kinases and NET-associated proteins.  
Studies on DAT revealed the importance of protein kinase B (Akt) for this trafficking 
effect of AMPH; constitutively active (CA) Akt reduced AMPH-induced decreases in DAT 
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surface expression (Garcia BG 2005).  This likely occurs by overpowering the effect of 
AMPH on Akt activity; AMPH decreases Akt’s ability to phosphorylate GSK3α in a dose-
dependent manner (Wei Y 2007).  This effect on DAT trafficking via Akt fits with other 
evidence that Akt activity supports basal cell surface DAT expression as part of the 
insulin signaling pathway (Carvelli L 2002; Garcia BG 2005).  However, our group has 
observed insulin-induced reduction of NET plasma membrane expression, rather than 
the augmentation seen for DAT, by cell surface biotinylation (Sabrina Robertson and 
Heinrich Matthies, unpublished; Carvelli L 2002), though others using uptake assays 
have seen only alterations in NET transport capacity, and not the proportion of NET on 
the surface, in response to insulin (Apparsundaram S 2001).  In either case, if AMPH-
induced regulation of NET trafficking involves Akt, it would probably not affect NET cell 
surface expression in the same way as for DAT.   
Akt’s involvement in AMPH regulation of NET trafficking seems likely, as both AMPH-
induced NET internalization and AMPH-induced inhibition of Akt via DAT require CaMKII 
(Dipace C 2007; Wei Y 2007).  Either chelation of intracellular Ca2+ or pharmacological 
inhibition of CaMKII prevent prevent AMPH-stimulated NET trafficking (Dipace C 2007), 
and the same CaMKII inhibitor blocks the reduction in Akt activity caused by AMPH (Wei 
Y 2007).  AMPH-induced NET internalization also involves an increase in the proportion 
of NET associated with the t-soluble N-ethylmaleimide-sensitive factor attachment 
receptor (SNARE) protein syntaxin1A, which also requires activation of CaMKII by 
AMPH (Dipace C 2007).  Association with syntaxin1A may increase NET’s probability of 
endocytosis, or even possibly mediate interaction with a member of the endocytosis 
machinery. 
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I-8 NET’s residence in endosomes 
Understanding of the mechanism by which AMPH causes internalization of NET 
necessitates identification of its intracellular destination; those proteins that regulate 
traffic into and out of such a site would likely be regulated by some component of the 
AMPH-induced signaling pathway.  AMPH exposure probably enriches NET in the same 
membrane compartment(s) through which it constitutively recycles.  We expect that NET 
recycles through a similar route to that of other SLC6 family members, which appear to 
move through the canonical endocytic recycling pathway, composed of the sorting 
endosome (SE) and the endocytic recycling compartment (ERC) (Fig. 3).    
Much of the work elucidating the functions of Rab GTPases has compared the effects of 
overexpressing wildtype Rab proteins with that of overexpressing point mutants on 
recycling of transferrin (Tf) and its receptor (TfR).  Dominant negative (DN) mutants 
either cannot bind guanine nucleotides or, like the Rab4 mutant we use, have lower 
affinity for GTP than for GDP (GDP-locked).  Constitutively active mutants have 
decreased GTPase activity and thus remain bound to GTP.  Constitutively active Rab5 
increases the rate of TfR endocytosis, and the GDP-locked form inhibits TfR 
internalization, implying that Rab5 functions in the earliest step of recycling, directing 
traffic from the plasma membrane to the SE (Stenmark H 1994).  Overexpression of 
wildtype Rab4 prevents release of iron from Tf, suggesting that Rab4 moves Tf out of 
acidic endosomes (van der Sluijs P 1992).  Wildtype Rab4 increases the proportion of 
TfR on the cell surface and GDP-locked Rab4 inhibits recycling of transferrin; Rab4 
probably transports cargo from the SE to the plasma membrane (van der Sluijs P 1992; 
McCaffrey MW 2001).  Alternatively, cargo may sort from the SE to the ERC.  As Rab11 
localizes to the ERC and DN Rab11 inhibits Tf recycling, Rab11 likely regulates traffic 
from the ERC to the plasma membrane (Ullrich O 1996; Ren M 1998). 
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Sorting 
endosome  Endocytic 
recycling 
compartment Rab4 Rab11 
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endosome  Endocytic 
recycling 
compartment Rab4 Rab11 
AMPH 
Figure 3.  Model of AMPH-induced NET trafficking through the classical 
endocytic pathway.  A.  Basal conditions: NET (green cylinders) constutively 
recycles through the SE and ERC.  Rab4 aids in trafficking from the SE to the 
plasma membrane and Rab11 aids in trafficking from the ERC to the surface.  
B.  Following semi-prolonged (30-60 minute) AMPH exposure.  An increased 
proportion of NETs on either or both endosomal populations due to faster 
endocytosis or slowed return to the plasma membrane leaves fewer NETs on 
the surface. 
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Immunoisolation of organelles containing TfR from DAT-PC12 cells revealed the 
residence of DAT on the same compartments at steady state (Melikian HE 1999).  This 
basal co-residence of DAT and TfR has also been demonstrated by confocal imaging of 
immunostained PAE DAT cells (Sorkina T 2005).  AMPH does indeed enrich DAT in the 
endosomes through which it recycles, as AMPH treatment increases colocalization of 
DAT with both Rab5, a marker of the SE, and Rab11, a marker of the ERC (Sorkina T 
2003). SERT likely traffics through the SE, as SERT and Rab4 physically associate upon 
exposure to high [5-HT], indicating their proximity even in basal conditions (Ahmed BA 
2008; Ahmed BA JB 2008).   GAT1 also seems to follow the canonical pathway; 
immunoisolated GAT1-containing vesicles include Rab5 and Rab11 (Deken SL 2003).  
That three closely related transporters all share the same recycling route all strongly 
support our hypothesis.   
Previous work on NET, however, has been interpreted as evidence of NET’s residence 
in synaptic vesicles (SVs), which does not preclude NET’s recycling through 
endosomes.  SVs may form from endosomes, as all SVs contain Rab5 and 
pharmacologic inhibition of endosome fusion depletes SVs (Fischer von Mollard G 1994; 
Rizzoli SO 2002).  Evidence of NET trafficking through SVs comes from the similar 
fractionation pattern of NET and [3H]NE on density gradients of PC12 cell  lysates 
preloaded with [3H]NE (Kippenberger AG 1999).  This does not exclude the possibility 
that NET and [3H]NE are in separate vesicles of similar size; the size of primary 
endocytic vesicles likely matches that of SVs.  NET’s differing distribution on sucrose 
density gradients from that of VMAT2, however, argues against NET’s residence on SVs 
(Leitner B 1999).  As results on this question conflict, clear conclusions remain elusive.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
II-1 Cell culture and transfection 
CAD cells are catecholaminergic and do not endogenously express NET (Qi Y 1997).  
hNET was cloned into pcDNA3, stably transfected into the CAD background, and 
selected and maintained with 200 µg/mL G418.   
Superior cervical ganglion (SCG) neurons were cultured according to Savchenko et. al. 
2003; briefly, SCGs were dissected from 1-3 day old C57/Bl6 mice and dissociated for 
30 min in 3 mg/mL collagenase/ 0.5 mg/mL trypsin (followed by termination with 10% 
FBS in DMEM).  Cells were plated and incubated with 3% fetal bovine serum in 
UltraCulture medium containing NGF for 2 hrs at 37° C to allow fibroblasts to adhere.  
Supernatant medium (containing SCG cells) was centrifuged, resuspended in medium 
supplemented with FBS, and cultured on poly-D-lysine- and collagen-coated glass-
bottom plates for 10-14 days before experiments (treating with 1 µM 5-fluoro-5-
deoxyuridine after 24 hrs). 
Rab11-FIP2 ∆C2-cherry and Rab4b(Q67L)-GFP are gifts of Dr. James Goldenring.  
Transient transfections were performed using Fugene 6 reagent (Roche) with 1 µg cDNA 
per 500,000 cells 24 hours before experiments.  For double transfections, 0.5 µg cDNA 
of each construct was used.   
 
II-2 Antibodies and other reagents 
Monoclonal anti-hNET 17-1 (MAb Technologies, Atlanta, GA), monoclonal anti- Na+/K+ 
ATPase α subunit (Developmental Studies Hybridoma Bank), polyclonal anti-Rab4 
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(AbCam), and polyclonal anti-Rab11a (Zymed) were used at dilutions of 1:1000, 1:100, 
1:1000, and 1:250-1:1000, respectively, for immunoblotting, with detection by enhanced 
chemiluminescence reaction.  Monoclonal anti-mNET 05 (MAb Technologies, Atlanta, 
GA), polyclonal anti-Rab4 (AbCam) and polyclonal anti-Rab11a (gift of Dr. James 
Goldenring) as described above were used at dilutions of 1:500, 1:250, and 1:1000 for 
immunocytochemistry.  Fluorescent secondary antibodies included highly cross-
absorbed donkey anti-mouse or rabbit IgG (Molecular Probes).  AMPH was obtained 
from Sigma (St. Louis, MO). 
 
II-3 Cell surface biotinylation 
Biotinylation experiments were performed on intact cells, allowing comparison of hNET 
surface expression (relative to total) across conditions, as described previously (Sung U 
2003; Garcia BG 2005; Miranda M 2005).  Briefly, CAD hNET cells were plated at a 
density of 1 x 106 per well in a six-well poly-(D-lysine) coated plate (Sigma).  Cells were 
starved of serum 1 hour prior to treatment, and immediately following treatment were 
washed with cold PBS containing Ca2+/Mg2+.  Cells were then incubated with 1.0 mg/mL 
sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate [NHS-SS-biotin] (Thermo 
Scientific, Rockford, IL) for 30 min, washed, quenched with 100 mM glycine, and 
extracted in lysis buffer (PBS Ca2+/Mg2+,  1% Triton 100-X, and 0.5 mM PMSF) (all on 
ice.  Membranes and nuclei were removed by centrifugation, and lysates were incubated 
with immobilized streptavidin beads (ThermoScientific) for 1 hr at room temperature.  
Total fractions were reserved, beads were washed three times in lysis buffer, and bound 
proteins eluted with 2X sample buffer containing 2-mercaptoethanol.  Proteins were then 
separated by SDS-PAGE and immunoblotted.  For estimation of relative amounts of 
proteins, the exposed films of the immunoblots were scanned, and band intensities were 
measured with Scion Image (Scion Corporation, Frederick, MD). 
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II-4 Immunostaining 
SCG neurons were serum starved for one hour in DMEM:F12 and treated with vehicle or 
AMPH for thirty minutes. Neurons were subsequently fixed with PBS Ca2+/Mg2+,/4% 
paraformaldehyde, washed three times with PBS Ca2+/Mg2+, permeabilized and blocked 
with PBS Ca2+/Mg2+/4% bovine serum albumin (BSA)/0.15% Tween-20, and 
immunostained with the appropriate antibody dissolved in PBS 4% BSA/0.05% Tween-
20.  Primary antibodies were visualized with the appropriate covalently labeled 
secondary antibody. Immunofluorescence was imaged using a Perkin Elmer UltraView 
confocal with a Nikon Eclipse 2000-U microscope equipped with a 60X lens with an N.A. 
of 1.49.  Image processing was performed using Image J and Adobe Photoshop.   
 
II-5 mNET internalization analysis 
Quantitation of mNET internalization analysis was achieved by first acquiring an intensity 
plot along a line through the center of each bouton image (using ImageJ).  This line 
extended outside the limits of the bouton so that the lowest intensity, assigned a value of 
zero, corresponds to a pixel with no staining.  Intensity values were normalized to the 
maximum value and the distance from the first peak to the last peak was divided into 20 
bins. The average pixel intensity for each bin calculated, then averaged with the pixel 
intensity for that bin for each bouton image in the same condition.   
 
II-6 Colocalization analysis 
Only images in which there was no pixel saturation were analyzed.  Background 
fluorescence was first subtracted in ImageJ by selecting an unstained area of each 
image (away from any neurons) and running the background subtraction plugin available 
at http://www.uhnresearch.ca/facilities/wcif/fdownload.html.  The intensity correlation 
  20 
quotient was then determined by running the ICA plugin for ImageJ developed by Tony 
Collins and Elise Stanley (Toronto Western Research Institute), also available at the 
above link.  The ICQ indicates whether intensity of staining for two proteins varies in 
synchrony over space; an ICQ of +0.5 means that in any pixel with a certain intensity of 
staining for one protein, the intensity of staining for the other protein studied will be 
exactly the same, while an ICQ of 0 signifies no relation between the two staining 
patterns and an ICQ of –0.5 indicates an inverse relationship.  Multiplying the difference 
of staining intensity at a particular pixel from the mean intensity for that protein across 
the analyzed space by the corresponding quantity for the other protein at the same pixel 
yields the product of the differences from the mean (PDM) for that pixel; plotting the 
PDMs for all pixels and dividing the number of pixels with positive PDM by the total 
number of pixels, then subtracting 0.5, yields the ICQ.   
 
II-7 Density gradient separation 
CAD hNET cells homogenized in PBS (cleared of nuclei by centrifugation at 1,000 x g 
for 10 minutes) were mixed with Opti-Prep to a final concentration of 13% and loaded 
into Sorvall Ultracrimp® tubes.  Centrifuging at 60,000 rpm in a vertical 70V6 rotor in a 
Sorvall Ultra 80 produced a density gradient.  400 µL fractions were collected by 
displacement with mineral oil using a Popper Micromatic pipetting assembly.The 
refractive index of each fraction was measured using a Bausch & Lomb Abbé 
refractometer.  The density was calculated from the refractive index by the formula: 
Density = 3.298 (refractive index) - 3.3967.  Proteins in all fractions were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotted, and 
estimation of relative amounts of each per fraction were determined as described for 
biotinylation experiments.  Relative amounts of a protein in each fraction were plotted as 
fractions relative to the total (sum of all fractions).  Where multiple experiments are 
  21 
averaged and plotted together, densities and band intensities of all fractions within bins 
of 0.005 g/mL are averaged and plotted as a single point. 
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CHAPTER III 
 
RESULTS 
 
III-1 AMPH leads to a decrease in surface NET expression   
Dipace et. al. demonstrated the ability of 10 µM AMPH to induce a reduction in surface 
NET expression in CAD cells stably expressing hNET (Dipace C 2007).  We sought to 
investigate this effect at a different time of exposure; the previous study included only 
results for 1, 5, 10, and 60 minute treatments and showed a significant decrease in 
surface hNET only at 60 minutes.  We chose to examine internalization at 30 minutes of 
AMPH treatment because, for later experiments, we wanted to minimize the possibility of 
lysosomal degradation of the transporter, shown for the DAT upon prolonged PKC 
activation (Miranda M 2005).  After treating, we incubated intact cells with biotin, allowing 
modification of all surface proteins and later collection by streptavidin.  Figure 4A shows 
representative immunoblots of biotinylated and total fractions from CAD hNET cells 
treated with either vehicle (CTRL) or 10 µM AMPH for 30 minutes at 37° C (to allow 
membrane trafficking).  The amount of hNET on the surface of cells treated with AMPH 
noticeably decreases in this experiment compared to CTRL, while levels of total hNET 
remain the same.  Figure 4B contains quantitation of multiple experiments normalized to 
CTRL; the proportion of hNET on the surface relative to total significantly decreases by 
81.3 ± 3.9 %.    
To replicate this finding in neurons at the single-bouton level, we treated neurons 
cultured from mouse superior cervical ganglia with 10 µM AMPH for 30 minutes and 
immunostained for murine NET (mNET).  Figure 5A shows representative confocal 
sections of boutons of neurons treated with either vehicle (CTRL) or AMPH.   
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Figure 4.  AMPH decreases surface hNET expression.  A, representative 
immunoblots of biotinylated and total fractions from CAD hNET cells treated with 10 
µM AMPH or vehicle (CTRL) for 30 min.  All bands from same blot and exposure.    
B, Quantification of immunoblots from multiple experiments.  Density of biotinylated 
samples was normalized to the density of the corresponding total sample and data 
are expressed as percentage of control.  Bars indicate the mean ± S.E. and are 
compared to control by one-way ANOVA, * indicates p< 0.05; n=3. 
Figure 5.  AMPH increases intracellular presence of NET in terminal boutons.  
A, representative images of confocal sections of boutons of SCG neurons treated 
with vehicle (CTRL) or 10 µM AMPH for 30 min and immunostained for mNET.  B, 
Quantification of multiple images.  Background subtracted pixel intensities were 
normalized to the peak intensity (assigned a value of 100) and averaged within 
corresponding bins (1/20th of peak-to-peak distance) for all images in each 
condition.  Data are expressed as mean ± S.E.and conditions are compared by two-
way ANOVA; *p<0.05, **p<0.01, ***p<0.001; n=9. 
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Qualitatively, more staining occurs inside the boutons in the AMPH-treated neurons.  We 
quantitated multiple boutons (Fig. 5B) from pixel intensity plots along lines drawn 
through the center of each bouton.  This line extended beyond the limits of the bouton 
into the extraneuronal space, so that the zero intensity value would represent no 
staining.  We then normalized each plot to its peak intensity (100%), divided the peak-to 
peak distance into 20 bins, and calculated the mean pixel intensity of mNET staining for 
each bin.  The intra-bouton staining is significantly higher in AMPH-treated neurons for 
11 bins, indicating that mNET is internalized with AMPH treatment.  This novel finding 
signifies that the AMPH-induced trafficking phenomenon is not limited to heterologous 
cells, and likely occurs in vivo. 
As we intended to investigate the destination of internalized NET biochemically, we 
tested whether separation of CAD hNET cell extracts across a density gradient would 
illustrate this effect of AMPH.  Representative immunoblots in Fig. 6A compare the 
distribution of hNET across the iodixanol (Optiprep®) gradient in cells treated with 
vehicle (CTRL) to that in cells treated with 10 µM AMPH for 30 minutes.  Basally, 
fractions at lighter densities (1.02-1.05 g/mL) contain the greatest proportion of hNET.  
Upon treatment with AMPH, the distribution shifts so that higher density fractions (1.09 
and 1.13 g/mL) contain the greatest proportion of hNET.  Figure 6C plots the data for 
this representative experiment.  We expected that those fractions hNET shifts away from 
upon AMPH exposure (those of lighter densities) would likely represent the plasma 
membrane, based on our other results (see Fig. 1 and 2).  To determine the densities at 
which cell surface membrane migrate, we immunoblotted the same density gradient 
fractions in Fig. 6A and C for the Na+/K+ ATPase α subunit (Fig. 6 B and D).  In both 
CTRL and AMPH treated cells, lighter density fractions (<1.05 g/mL) contain all Na+/K+ 
ATPase, indicating that these fractions do indeed represent the plasma membrane.  
That the low density hNET peak and the Na+/K+ ATPase peak do not correspond exactly  
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Figure 6.  AMPH decreases the proportion of NET that fractionates at low 
densities, partially overlapping with Na+/K+ ATPase.  A-B, immunoblots of 
iodixanol density gradient fractions from CAD hNET cells treated with either vehicle 
(CTRL) or 10 µM AMPH for 30 min.  C-D, plots of band densities of blots in A-B.  E-H, 
mean band densities of multiple experiments plotted on expanded density axes; E-F, 
surface fractions, G-H, intracellular.  E and G, hNET; F and H, Na+/K+ ATPase.  n= 3. 
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may indicate that the two proteins reside in different subdomains of the plasma 
membrane, possibly a recycling domain and a domain from which proteins cannot leave 
the plasma membrane.  Figures 3E-H plot mean distributions of hNET (Fig. 6E-F) and 
Na+/K+ ATPase (Fig. 6G-H) from several experiments, with the x axis expanded to show 
either the surface fractions (Fig. 6E and 6G) or the intracellular fractions (Fig. 6F and 
6H).  Figure 6E shows a trend towards a decrease in the proportion of hNET in the 
surface fractions, especially noticeable between 1.025 and 1.03 g/mL, and Figure 3F 
shows a trend towards an increase in the proportion of hNET in intracellular fractions.  
Na+/K+ ATPase does not shift to low densities with AMPH treatment across experiments.  
Thus, the shift in Fig. 6A-B represents a shift of hNET away from the cell surface and 
into an intracellular destination. 
 
III-2 AMPH increases colocalization of NET with Rab4 and Rab11 
To characterize the intracellular destination of hNET upon AMPH-induced internalization, 
we immunoblotted density gradient fractions from CAD hNET cells treated for 30 
minutes with 10 µM AMPH for Rab4, a marker of the SE, and Rab11, a marker of the 
ERC.  Figure 4 shows a representative experiment, in which hNET is enriched in higher 
density fractions of 1.09 and 1.13 g/mL (Fig. 7A, immunoblot; Fig. 7B, plot).  These high 
density fractions also contain the greatest proportion of Rab4 (Fig. 7C, immunoblot; Fig. 
7D, plot).  Rab4’s distribution does not change with AMPH treatment (Fig. 7E).  Co-
localization of hNET upon AMPH exposure with Rab4 in the same density gradient 
fractions suggests that AMPH treatment causes increased accumulation of hNET in the 
SE.   High density fractions (1.1 and 1.15 g/mL) again contain the greatest proportion of 
hNET following AMPH exposure in a separate experiment (Fig. 7F, immunoblot, Fig. 7G, 
plot).  Rab11 exists predominantly in high density fractions, with the greatest proportion  
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Figure 7.  hNET cofractionates with Rab4 and Rab11 following AMPH 
treatment. CAD hNET cells were treated with vehicle or 10 µM AMPH for 30 
min. A, C, E, G, representative experiment comparing iodixanol density gradient 
distribution of hNET with that of Rab4 in AMPH-treated cells.  A and E, 
immunoblots; C and G, plots of band densities as fraction of total.  A and C, 
hNET; E and G, Rab4.  I, comparison of Rab4 distribution in vehicle-treated 
cells with that in AMPH-treated across multiple experiments (n=3). B, D, F, H, 
separate experiment comparing distribution of hNET with that of Rab11.  B and 
F, immunoblots; D and H, plots of band densities as fraction of total.  B and D, 
hNET; F and H, Rab11. J, comparison of Rab11 distribution in vehicle-treated 
cells with that in AMPH-treated across multiple experiments (n=3). 
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in those enriched with hNET by AMPH (Fig. 7H, immunoblot, Fig. 7I, plot).  Rab11’s 
distribution does not change with AMPH treatment (Fig. 7J).  Similar to Rab4, co-
localization of hNET with Rab11 in the same fractions suggests AMPH-induced 
accumulation of hNET in the ERC.  In order to replicate these findings in neurons at the 
single bouton level, we treated SCG neurons with either vehicle or 10 µM AMPH for 30 
minutes and immunostained for mNET and either Rab4 (Fig. 8A-B) or Rab11 (Fig. 8C-
D).  The example images in Figure 8A show no noticeable colocalization  between 
mNET and Rab4 in the CTRL condition, and a small amount of overlap of staining after 
exposure of neurons to AMPH.  We compiled the results of multiple experiments by 
calculating the intensity correlation quotient (ICQ) for each bouton and determining the 
mean (Fig. 8B) (Li et. al. 2004).  In the CTRL condition, the ICQ of mNET and Rab4 
staining is -0.01267 ± 0.02527 (n=12), indicating that the two patterns do not correlate, 
while upon AMPH treatment, the ICQ is 0.1015 ± 0.01584 (n=12 boutons, two 
experiments), meaning that mNET and Rab4 staining vary in partial synchrony (Fig. 8B).  
This result confirms that of our density gradient experiments, again suggesting AMPH-
induced accumulation of NET in the SE. 
We also applied this analysis to confocal images of boutons from SCG neurons 
immunostained for mNET and Rab11.  The representative images in Fig. 8C show slight 
overlap of mNET and Rab11 staining in boutons of SCG neurons treated with vehicle 
(CTRL), and a much more noticeable colocalization upon AMPH exposure.  Mean ICQ 
values from multiple images in each condition reveal the consistency of this pattern 
across experiments; the ICQ of mNET and Rab11 increases from 0.1043 ± 0.02476 
(n=13) in control conditions to 0.2046 ± 0.02265 (n=13 boutons, two experiments) upon 
AMPH exposure (Fig. 8D). 
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Fig. 8  AMPH increases colocalization of hNET with Rab4 and Rab11.  A 
and C, confocal sections of SCG boutons treated with either vehicle (CTRL) or 
10 µM AMPH for 30 min.  A, Immunostaining for mNET and Rab4; C, mNET 
and Rab11.  B and D, Plots of intensity correlation quotients (ICQ) in each 
condition.  B, ICQ of NET and Rab4, n= 12, 2 experiments, D, ICQ of NET and 
Rab11, n= 13, 2 experiments. 
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III-3 NET trafficking involves Rab4 and Rab11 function 
We investigated not only the sites in which NET accumulates upon AMPH treatment, but 
also the functional roles Rab4 and Rab11 play in AMPH-regulated NET trafficking.  Rab  
proteins do not simply identify endosomal populations, but also facilitate the delivery of 
vesicles to destination compartments (Zerial M 2001).  Rab4 controls traffic from the SE 
to the plasma membrane (van der Sluijs P 1992).  Because NET accumulates in Rab4-
positive sites with AMPH treatment (Fig. 7A-D and 8A-B), we suspected that NET may 
be returned to the cell surface through this Rab4-regulated pathway.  To address this 
question, we disrupted Rab4 function by transiently transfecting either a GDP_locked 
(dominant negative) form of the protein, Rab4 S22N (DN Rab4), or empty vector into 
CAD hNET cells and comparing AMPH-induced internalization by cell-surface 
biotinylation.  As shown in the representative immunoblots in Fig. 9A, the proportion of 
hNET in the surface fraction relative to that in the total decreases visibly with both 10- 
and 30-minute exposures to 10 µM AMPH (compared to vehicle treatment) in vector-
transfected cells, while hNET surface expression remains the same following either 
exposure time in cells transfected with DN Rab4.  Quantitation of multiple experiments in 
Figure 9B demonstrate that AMPH induces noticeable internalization at both time points 
(88 ± 2.5 % at 10 minutes and 84 ± 3.5 % at 30 minutes) in vector-transfected cells, and 
there is no internalization after AMPH exposure in DN Rab4-transfected cells.  This 
result implies that AMPH-regulated NET trafficking does indeed involve Rab4. 
Traffic from the ERC to the plasma membrane requires Rab11, and NET also 
accumulates in Rab11-positive sites (Fig. 7F-I, 8C-D), so we hypothesized that AMPH-
regulated NET trafficking involves Rab11 (Ren M 1998; Trischler M 1999).  Our 
approach to test this again involved disrupting Rab11 function and measuring AMPH-
induced internalization.  We blocked Rab11 function by transfecting with a dominant 
negative form of Rab11 family interacting protein 2 (Rab11 FIP2) lacking the C2 domain  
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Figure 9.  Disrupting function of Rab4 or Rab11 prevents AMPH-induced NET 
internalization.  A-B, CAD hNET cells transfected with DN Rab4 were treated with 
vehicle (0) or 10 µM AMPH for the indicated times and subjected to cell-surface 
biotinylation.  A, representative immunoblots of surface and total fractions.  B, 
quantification of multiple experiments.  C-D, CAD hNET cells transfected with DN 
FIP2 treated as previous.  C,  representative immunoblots of surface and total 
fractions.  D, quantification of multiple experiments. E-F, CAD hNET cells 
transfected with both DN Rab4 and DN FIP2.  E,  representative immunoblots of 
surface and total fractions.  F, quantification of multiple experiments. * indicates 
p<0.05 compared with control.  n=3 for all experiments. 
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(DN FIP2), which severely disrupts plasma membrane recycling (Hales CM 2002).  
Translocation of Rab11 FIP2 to the plasma membrane from the ERC requires the C2 
domain, which binds phosphatidylinositol-(3,4,5)-triphosphate (PIP3) and phosphatidic 
acid (Lindsay AJ 2004).  Rab11 FIP2 (both full-length and the DN truncation) interacts 
with both Rab11 and the motor protein myosin Vb, possibly acting as an adaptor 
between the two (Hales CM 2001).  The proportion of hNET on the surface of vector-
transfected CAD hNET cells noticeably decreases upon 10- or 30-minute AMPH 
treatment compared to vehicle-treated controls, while the level of surface hNET is 
unaltered by AMPH in cells transfected with DN FIP2 (Fig. 9C).  These data are 
consistent across multiple experiments; significant AMPH-induced internalization occurs 
in vector-transfected cells (76.3± 6.7 % at 10 m and 80.74± 4.6 % at 30 m), while we 
observe no effect of AMPH on surface levels of hNET in DN FIP2-transfected cells (Fig. 
9D).  DN FIP2’s ability to block AMPH-induced internalization likely means that AMPH-
regulated NET trafficking also entails Rab11 function. 
Our results suggest that reducing the function of either of these Rabs may increase 
return of NET to the plasma membrane through the route involving the other Rab.  In the 
case of DN Rab4, blocking traffic from the SE to the surface might increase traffic to the 
ERC, increasing the amount of NET residing there.  This could then drive NET through 
the Rab11-regulated pathway to the plasma membrane, perhaps by exceeding the 
capacity of the ERC to store NET.  Therefore, we examined whether blocking function of 
both Rab4 and Rab11 simultaneously would have a different effect on AMPH-induced 
NET internalization from that of blocking either alone.  Contrary to our expectation, 
surface hNET expression is unchanged upon AMPH treatment in CAD hNET cells 
double-transfected with both DN Rab4 and DN FIP2, though there appears to be a trend 
toward an increase at 10 min, while surface hNET expression in vector-transfected cells 
decreases at both timepoints (54.99± 7.69 % at 10 min and 38.55± 6.29 % at 30 min) 
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(Fig. 6E, immunoblots, 6F, quantitation of multiple experiments).  As this result mimics 
that of blocking either Rab4 or Rab11 function alone, the effects of blocking Rab4 and 
Rab11 function on AMPH-induced NET internalization appear independent of one 
another.    
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CHAPTER IV 
 
DISCUSSION 
 
IV-1 AMPH-induced NET internalization in boutons 
AMPH exposure has been shown to cause a decrease in cell surface expression of 
NET; however, this effect has only been investigated in heterologous cells in a single 
report (Dipace C 2007).  AMPH-induced internalization of DAT, however, has been 
studied in greater detail (Saunders C 2000; Kahlig KM 2004; Garcia BG 2005; Gnegy 
ME 2004; Johnson LA 2005a; Johnson LA 2005b; Kahlig KM 2006; Wei Y 2007; 
Boudanova E 2008).  Further, a single, high dose of AMPH induces a significant 
reduction of DA uptake in striatal synaptosomes when administered one hour prior to 
preparation, indicating the physiological relevance of this phenomenon (Fleckenstein AE 
1999).   We reveal the first evidence of AMPH-induced redistribution of NET away from 
the plasma membrane in noradrenergic neurons, implying that this effect on NET 
contributes to AMPH’s ability to increase extracellular NE in vivo.  Further, our 
demonstration that AMPH leads to internalization of NET in boutons implies that AMPH 
transport capacity would decrease at sites of NE release, affecting extracellular NE 
faster than would AMPH-induced trafficking at the soma.   
 
IV-2 Basal mNET distribution in neurons 
Our mNET immunostaining results, showing most NET on the surface of terminal 
boutons in basal, untreated conditions, contrast earlier ultrastructural findings in the rat 
prefrontal cortex using the polyclonal anti-mNET antibody 43411 (Miner LH 2003; Miner 
LH 2006).  Many factors could contribute to this difference; most importantly, we 
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included Ca2+ in our perfusion solutions, while animals in the immuno-electron 
microscopy studies were perfused with PBS lacking Ca2+ prior to sectioning and staining.  
We have found that incubation of SCG neurons in PBS lacking Ca2+ leads to an increase 
in intracellular staining by the monoclonal mNET antibody (H. Matthies, unpublished 
results).  This observation appears to conflict with the AMPH-induced increases in 
intracellular Ca2+ associate with NET internalization (Dipace C 2007).  Zero-Ca2+-
induced NET internalization would not likely involve decreased CaMKII activity, as 
inhibition of CaMKII prevents AMPH-induced NET internalization and CaMKII activity 
supporting both basal NET surface expression and leading to NET internalization seems 
improbable (Dipace C 2007).   Decreased intracellular Ca2+ might inhibit Akt 
independently of CaMKII, through some other kinase or phosphatase.  
Additionally, the epitopes for the two antibodies differ: the monoclonal antibody we use 
recognizes residues 5-17, while the polyclonal antibody recognizes residues 585-607 
(Matthies in press, Schroeter S 2000).  NET’s C terminus may be phosphorylated or 
bound to some interacting protein while it resides on the plasma membrane, preventing 
detection by 43411.  A difference in NET surface expression between noradrenergic 
projections to the cortex and SCG neurons does not likely account for the discrepancy, 
as we can alter NET’s cellular distribution by Ca2+ manipulation.  
 
IV-3 Similarity to other SLC6 transporters 
The intracellular destination of NET internalized upon AMPH exposure was previously 
undescribed.  In this report we provide evidence, both by biochemical and imaging 
methods, that AMPH increases NET’s accumulation in Rab4- and Rab11-positive sites 
(Fig. 7-8), which may represent the SE and ERC.  Our demonstration of NET’s 
colocalization with Rab4 after substrate (AMPH) exposure is consistent with the finding 
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that the serotonin transporter colocalizes with Rab4 after exposure to high 
concentrations of serotonin (Ahmed BA 2008).  Our findings also agree with those for 
AMPH regulation of DAT trafficking: that AMPH increases its colocalization with a 
different SE marker, Rab5, and with Rab11 (Sorkina T 2005).  This similarity in 
trafficking routes among members of the SLC6 gene family points to a possible common 
signaling pathway activated by substrate influx that supports net movement of these 
related transporters to endosomes.   Stronger support might come from future 
immunoisolation studies, which could show that NET resides on the same membranes 
as Rab4 and Rab11.  Additionally, future investigation might compare the distribution of 
NET in AMPH-treated cells to that of other markers to show that Rab4-positive 
membranes represent the SE and Rab11-positive fractions represent the ERC. 
We also show that some NET fractionates at high densities, overlapping with Rab4- and 
Rab11-containing fractions, even in the basal state (Fig. 6 and 7).  Further, we find 
spatially synchronous colocalization of NET with Rab11 in resting conditions, though of a 
lesser degree than in AMPH-treated neurons (Fig. 8).  These results support our 
proposal that AMPH alters rates of trafficking into and/or out of the same compartments 
through which NET constitutively recycles.  That these recycling compartments appear 
to contain Rab4 and Rab11, indicating the classical endosomal pathway, also agrees 
with previous findings on DAT, SERT, and GAT1 (Melikian HE 1999; Deken SL 2003; 
Sorkina T 2005; Ahmed BA 2008). 
 
IV-4 Possible relation to AMPH-induced signaling 
The signaling pathway involved in AMPH-induced trafficking of DAT and NET has been 
partially elucidated.  Increased intracellular Ca2+ and activation of the kinases CaMKII 
and Akt are all part of the cascade leading to decreased surface expression of 
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transporter, but how these steps cause either faster internalization or slower return of 
transporter to the surface is unknown (Dipace C 2007; Wei Y 2007).  By providing 
evidence for NET’s increased residence in Rab4- and Rab11-positive compartments, we 
suggest a future direction for study of this regulation.  Rab4 and Rab11 themselves may 
be targets of these kinases or intermediate players yet to be identified, as we have 
shown their function is involved in AMPH-induced NET internalization (Fig. 9).  
Alternatively or in addition, as the Rab4- and Rab11-positive compartments likely 
represent the SE and ERC, respectively, other proteins known to regulate traffic in and 
out of these sites may be involved in AMPH’s effects on NET trafficking.   
Future work may lead to a complete signaling cascade including the GTPase activating 
protein (GAP) or guanine nucleotide exchange factor immediately upstream of a Rab, 
possibly Rab4 or Rab11.  A similar story has been detailed for the SLC2 member 
glucose transporter 4 (GLUT4), which facilitates inward diffusion of glucose and traffics 
to the cell surface upon insulin stimulation.  Insulin signaling activates Akt, which 
phosphorylates Akt substrate of 160 kDa (AS160) (Cross DA 1995; Kane S 2002).  
Phosphorylation of AS160 inhibits its GAP activity for substrate Rabs including Rab8, 
Rab10, and Rab14, which are all involved in trafficking GLUT4 to the cell surface 
(Ishikura S 2007; Sano H 2007).  Thus, Akt activation by insulin, through AS160, 
increases the level of these Rabs’ activity, which speeds traffic of GLUT4 to the cell 
surface (Sano H 2003). 
 
IV-5 NET reserve pool hypothesis 
NET may return to the plasma membrane directly from either of these two 
compartments, and the rates of return differ considerably: recycling through only the SE 
requires approximately two minutes (Dunn KW 1989; Mayor S 1993), while traffic 
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through both the SE and ERC takes about ten minutes (Mayor S 1993).  That NET may 
reside in two distinct locations inside the cell upon AMPH treatment suggests that there 
may be two separate means of regulation of return to the surface.  The ERC may 
provide a reserve pool of NET, either in endosomes themselves or in post-endosomal 
vesicles, while NET could move directly from the SE to the plasma membrane.   
A NET storage pool would echo the vesicular trafficking pattern of GLUT4, which 
recycles first through the SE and ERC, before GLUT4 storage vesicles (GSV) form from 
the ERC (Fischer Y 1997; Kessler A 2000; Foster LJ 2001; Zeigerer A 2002).  Insulin 
may preferentially stimulate traffic from GSV to the cell surface, though it also speeds 
movement of GLUT4 through the endosomal pathway to the GSV (Becker C 2001; 
Foster LJ 2001; Zeigerer A 2002).  Insulin-regulated traffic of GLUT4 both from the ERC 
to GSV and from GSV to the membrane involves Rab11; as AMPH-regulated NET traffic 
also involves Rab11, the GTPase could serve a similar dual function if the NET reserve 
pool were separate from the ERC (Zeigerer A 2002). 
 
IV-6 Effect of blocking Rab function on AMPH-induced NET internalization 
Our original model would predict that transfection of DN Rab4 or DN FIP2 would reduce 
the rate of return of NET to the cell surface, thereby enhancing the internalization effect 
of AMPH.  We find the opposite, that transfection of these constructs blocks 
internalization of NET in response to AMPH treatment, increasing the proportion of NET 
on the plasma membrane relative to that in AMPH-treated vector-transfected cells.  
Though we based our model on the consensus view of Rab4 and Rab11 function in 
endocytic recycling, our results parallel previous observations of the effect of transfection 
of a DN Rab11 construct on carbachol-induced M4 muscarinic acetylcholine receptor 
internalization (Volpicelli LA 2002; Reiner C 2008).  In these studies, the GDP-locked 
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form of Rab11a prevented carbachol-induced accumulation of M4 in the ERC and 
reduced the carbachol-induced decrease in M4 surface expression.   
The authors of the latter study, as well as others working on GLUT4, have suggested 
that Rab11 may act in endocytosis of membrane proteins, though neither these 
investigators nor others have tested this directly (Uhlig M 2005; Reiner C 2008).  In any 
case, our model appears too simple to explain our data; either Rab4 and Rab11 have 
more complex functions than those we supposed, or an additional GTPase may aid in 
return of NET to the plasma membrane.  Further, our overexpression of only the DN 
constructs in a background of variable levels of NET expression may have minimized the 
effects of blocking Rab function, which may be more pronounced if NET were 
overexpressed as well.  Our concern was only whether the function of these small 
proteins contributes to AMPH-induced NET internalization, and future studies may 
investigate the mechanism by which Rab4 and Rab11 regulate NET trafficking.   
 
IV-7 Conclusions 
In summary, we have shown that AMPH induces an accumulation of NET intracellularly, 
including in Rab4- and Rab11-positive sites, and that the function of these GTPases is 
involved in this AMPH-regulated trafficking effect.  Treatment of SCG neurons with 
AMPH causes a redistribution of NET that increases its intracellular presence in terminal 
boutons.  AMPH exposure increases the proportion of NET in high-density fractions 
which also contain the greatest proportions of Rab4 and Rab11, and increases the 
proportion of NET colocalized with these markers of the SE and ERC, respectively, as 
determined by the ICA quantitative method.  Finally, disrupting the function of Rab4 and 
Rab11, either separately or in combination, blocks AMPH-induced NET internalization.  
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These findings support our hypothesis that AMPH increases NET’s presence in 
endosomal compartments. 
 
IV-8 Significance 
Better understanding of AMPH’s regulation of NET subcellular distribution may enhance 
insight into AMPH’s effectiveness as a therapy as well as its undesired effects.  More 
detailed investigation of the molecules involved in the AMPH-induced reduction in NET 
surface expression might also reveal possible sites of misregulation leading to disorders 
thought to involve NET, such as depression, hypertension, and ADHD.  If future work 
identifies a unique effector in the AMPH-induced signaling pathway that causes NET 
internalization via endosomes, this could even lead to development of alternative drugs 
that selectively induce this effect without affecting DAT trafficking or transmitter efflux 
through either transporter.  Such novel therapies might benefit ADHD patients and 
abusers of amphetamines. 
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